Edison, NJ, United States of America

Alejandro Crespo

USPTO Granted Patents = 9 


Average Co-Inventor Count = 11.5

ph-index = 1

Forward Citations = 10(Granted Patents)


Location History:

  • Edison, NJ (US) (2015 - 2019)
  • Westfield, NJ (US) (2019)

Company Filing History:


Years Active: 2015-2019

Loading Chart...
Loading Chart...
9 patents (USPTO):

Title: Alejandro Crespo: Innovator in Therapeutic Compounds

Introduction

Alejandro Crespo is a notable inventor based in Edison, NJ (US), recognized for his contributions to the field of therapeutic agents. He holds a total of 9 patents, focusing primarily on compounds that target central nervous system disorders.

Latest Patents

Crespo's latest patents include innovative compounds such as triazolyl pyrimidinone and pyrazolyl pyrimidinone, both of which serve as phosphodiesterase 2 (PDE2) inhibitors. These compounds are designed to treat various neurological and psychiatric disorders, including schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), and Huntington's disease. The therapeutic potential of these compounds lies in their ability to address conditions associated with striatal hypofunction or basal ganglia dysfunction.

Career Highlights

Throughout his career, Crespo has worked with prominent companies, including Merck Sharp & Dohme Corporation and MSD R&D (China) Co., Ltd. His work in these organizations has significantly contributed to advancements in pharmaceutical research and development.

Collaborations

Crespo has collaborated with esteemed colleagues such as Dong-Ming Shen and Christopher Joseph Sinz, further enhancing the impact of his research in the field.

Conclusion

Alejandro Crespo's innovative work in developing therapeutic compounds showcases his commitment to addressing critical health issues. His contributions continue to influence the landscape of neurological and psychiatric treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…